CRSP CRISPR Therapeutics AG
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1674416 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-34.3%
TTM net income YoY6.6%
TTM EPS YoY14.6%
Revenue 3-yr CAGR-47.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-2,114.8%
Net margin-1,812.1%
FCF margin-1,496.6%
EBITDA margin-2,041.3%
Returns
ROE-25.6%
ROA-19.0%
ROIC (approx.)-22.9%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets35.5%
Debt / equity0.36x
Current ratio16.21x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.82x
Accruals ratio-3.4%
Payout ratio—
Capex / revenue8.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $12.67M | $10.18M | $1.46M | $864,000 | $889,000 | $892,000 | $865,000 | $35.69M |
| R&D expense | $71.89M | $67.15M | $68.57M | $83.53M | $58.90M | $69.89M | $72.48M | $82.16M |
| SG&A expense | $17.87M | $17.55M | $17.18M | $18.40M | $16.93M | $18.92M | $19.30M | $18.12M |
| Operating income | -$130.04M | -$117.27M | -$130.25M | -$154.76M | -$132.06M | -$229.32M | -$148.42M | -$64.59M |
| Interest expense | $3.33M | $3.32M | $553,000 | — | $0 | $0 | $0 | — |
| Pretax income | -$111.36M | -$90.19M | -$122.09M | -$130.00M | -$105.82M | -$207.26M | -$134.89M | -$36.61M |
| Income tax | $74,000 | $960,000 | $839,000 | $614,000 | $619,000 | $1.29M | $1.11M | $700,000 |
| Net income | -$111.44M | -$91.15M | -$122.93M | -$130.61M | -$106.44M | -$208.55M | -$136.00M | -$37.31M |
| EBITDA | -$125.84M | -$112.97M | -$125.93M | -$149.10M | -$127.66M | -$224.72M | -$143.69M | -$59.75M |
| EPS (basic) | -1.15 | -0.94 | -1.28 | — | -1.17 | -2.40 | -1.58 | — |
| EPS (diluted) | -1.15 | -0.94 | -1.28 | — | -1.17 | -2.40 | -1.58 | — |
| Weighted avg. shares (diluted) | 96.74M | 96.51M | 96.05M | — | 91.31M | 87.07M | 85.94M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $192.03M | $291.34M | $423.31M | $347.56M | $286.50M | $193.62M | $235.18M | $298.26M |
| Short-term investments | $2.08B | $2.07B | $2.02B | $1.63B | $1.63B | $1.53B | $1.62B | $1.61B |
| Receivables | — | — | — | $0 | $0 | $0 | $0 | $25.00M |
| Current assets | $2.29B | $2.37B | $2.45B | $1.99B | $1.93B | $1.73B | $1.87B | $1.94B |
| PP&E, net | $104.30M | $108.07M | $112.17M | $115.85M | $120.83M | $124.93M | $129.43M | $134.09M |
| Intangibles | — | — | — | — | — | — | — | $0 |
| Total assets | $2.56B | $2.65B | $2.73B | $2.27B | $2.25B | $2.03B | $2.17B | $2.24B |
| Current liabilities | $140.96M | $132.90M | $136.29M | $149.12M | $118.96M | $104.36M | $119.45M | $87.78M |
| Long-term debt | $586.93M | $586.20M | $585.47M | $0 | — | — | — | — |
| Total debt | $586.93M | $586.20M | $585.47M | $0 | — | — | — | — |
| Total liabilities | $908.34M | $904.22M | $911.26M | $343.43M | $329.33M | $318.59M | $336.94M | $309.95M |
| Shareholders' equity | $1.65B | $1.75B | $1.81B | $1.92B | $1.92B | $1.71B | $1.83B | $1.93B |
| Net debt | $394.91M | $294.86M | $162.16M | -$347.56M | — | — | — | — |
| Shares outstanding | 96.86M | 96.66M | 96.39M | 95.89M | 93.87M | 88.38M | 86.36M | 85.74M |
| Cash flow statement | ||||||||
| Operating cash flow | -$89.68M | -$83.50M | -$108.90M | -$92.55M | -$84.63M | -$113.88M | -$53.95M | -$50.03M |
| Capital expenditure | $414,000 | $648,000 | $504,000 | $517,000 | $74,000 | $117,000 | $206,000 | $254,000 |
| Free cash flow | -$90.10M | -$84.15M | -$109.40M | -$93.07M | -$84.71M | -$114.00M | -$54.15M | -$50.28M |
| Investing cash flow | -$14.09M | -$55.66M | -$410.74M | $37.20M | -$119.23M | $69.98M | -$19.75M | $105.83M |
| Financing cash flow | $4.45M | $7.18M | $591.91M | $116.41M | $296.77M | $2.26M | $10.59M | $16.88M |
| Depreciation & amortization | $4.20M | $4.30M | $4.32M | $5.66M | $4.40M | $4.60M | $4.74M | $4.84M |
| Stock-based compensation | $17.96M | $17.32M | $16.32M | $18.08M | $16.60M | $17.61M | $20.21M | $21.95M |
Free plan shows the latest 8 periods; Pro shows all 47 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.